Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia

Cancer

Volumn 106, Issue 11, 2006, Pages 2406-2411

  Gangat, Naseema ^a   Wolanskyj, Alexandra P ^a   Schwager, Susan M ^a   Mesa, Ruben A ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Essential thrombocythemia; Estrogen; Hormones; Thrombosis

Indexed keywords

CHOLESTEROL; ESTROGEN; GLUCOSE; HEMOGLOBIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DIABETES MELLITUS; DISEASE ASSOCIATION; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTHEMIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOSIS; THROMBOSIS;

EID: 33646858572     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21891     Document Type: Review

References (30)

1. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors: tumours of the haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer (IARC) Press, 2001:17-44.
2. Tefferi A, Gilliland DG. Classification of myeloproliferative disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol. 2005 (in press).
3. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol. 1999;61:10-15.
4. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.
5. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15:173-189.
6. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663.
7. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complications rates, and prognostic factors. Mayo Clin Proc. 2006;81:159-166.
8. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215-232.
9. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
10. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
11. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
12. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
13. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275-290.
14. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1998;877:i-vii, 1-89.
15. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
16. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360:942-944.
17. Farley TM, Meirik O, Marmot MG, Chang CL, Poulter NR. Oral contraceptives and risk of venous thromboembolism: impact of duration of use. Contraception. 1998;57:61-65.
18. Grady D, Hulley SB. Hormones to prevent coronary disease in women: when are observational studies adequate evidence? Ann Intern Med. 2000;133:999-1001.
19. Stokes J 3rd, Kannel WB, Wolf PA, D'Agostino RB, Cupples LA. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study-30 years of follow-up. Hypertension. 1989;13(5 Suppl):I13-18.
20. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002:288:321-333.
21. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965-1976.
22. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 1999;19:700-703.
23. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
24. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005;94:17-25.
25. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost. 1994;71:548-552.
26. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364-2368.
27. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150-154.
28. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 × 10(9)/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1998;100:15-23.
29. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol. 2001;80:74-78.
30. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 1993;83:198-203.